Drug Profile
Research programme: aerosolised ISS - Dynavax
Alternative Names: Aerosolised ISS research programme - Dynavax; Biodefense applications research programme- DyanvaxLatest Information Update: 16 Apr 2008
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Viral infections
Most Recent Events
- 16 Apr 2008 Discontinued - Preclinical for Viral infections in USA (Intrapulmonary)
- 25 Sep 2006 Aerosolised immunostimulatory sequence is still in preclinical trials in the US
- 12 Nov 2003 Preclinical trials in Viral infections in USA (Intrapulmonary)